Učitavanje...
The PI3Kδ inhibitor idelalisib suppresses liver and lung cellular respiration
Idelalisib (an inhibitor of phosphatidylinositol-3-kinase-delta) is approved for treatment of B-cell malignancies, with a Boxed Warning concerning potentially fatal hepatic, lung, and intestinal toxicities. The mechanisms of these tissue-specific adverse events have yet to be elucidated. This in vit...
Spremljeno u:
| Izdano u: | Int J Physiol Pathophysiol Pharmacol |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
e-Century Publishing Corporation
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4697667/ https://ncbi.nlm.nih.gov/pubmed/26823960 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|